Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients
Status:
Completed
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial was to find an optimal dose for a new trial drug - degarelix
(FE200486) - in the treatment of prostate cancer. Furthermore the safety of the drug was
studied. Patients participating were treated with FE200486 on one occasion. Thereafter they
came in for visits following a specific schedule until blood samples showed that there was no
further effect.